

Group V. Claims 37 and 106, drawn to method of treatment using antibodies to homodimeric protein, classified in class 424, subclass 130.1.

Group VI. Claims 51 and 106, drawn to method of treatment using protein, classified in class 514, subclass 2.

Group VII. Claims 52 and 113, drawn to a diagnostic assay for protein, classified in class 435, subclass 7.1.

Group VIII. Claims 53 and 115, drawn to a device comprising a membrane and cells expressing protein, classified in class 435, subclass 382.

Group IX. Claim 54, drawn to a binding assay using protein, classified in class 435, subclass 7.1.

Group X. Claims 55 and 116, drawn to gene therapy, classified in class 14, subclass 44.

Group XI. Claims 56 and 117, drawn to a transgenic animal, classified in class 800, subclass 8.

Group XII. Claims 58-60, 68, 107, 108 and 118, drawn to heterodimeric protein, classified in class 530, subclass 350.

Group XIII. Claim 69, drawn to assay for compounds that modulate heterodimer activity, classified in class 435, subclass 7.2.

Group XIV. Claims 70, 72, 73, 75, 92, 103-105, 107 and 108, drawn to antibodies to β 10 heterodimers, classified in class 530, subclass 387.9.

Group XV. Claim 76, drawn to immunoassay for β 10 homodimer, classified in class 436, subclass 501.

Group XVI. Claims 77, 122 and 124, drawn to immunoassay for heterodimer, classified in class 436, subclass 501.

Group XVII. Claim 106, drawn to a method of treatment using homodimer, classified in class 514, subclass 2.

Group XVIII. Claim 106, drawn to a method of treatment using a heterodimer, classified in class 514, subclass 2.

Group XIX. Claim 106, as drawn to a method of treatment using antibodies to a heterodimer, classified in class 424, subclass 130.1.


Group XX. Claims 120 and 121, drawn to heterodimeric fusion protein, classified in class 530, subclass 350.

Group XXI. Claim 123, drawn to a device comprising a membrane and cells expressing heterodimeric protein, classified in class 435, subclass 382.

The present invention relates to a novel beta-like member of the glycoprotein hormone family. Applicants submit that the subject matter of the instant claims is sufficiently related, and would not require unduly burdensome searching on the part of the Patent and Trademark Office to search all of the groups recited in the Restriction Requirement.

Nevertheless, Applications hereby elect Group I, claims 1-8, 10, 11, 46-50, 61-67, 111 and 112, directed to nucleic acids, vectors, host cells, expression, and monomeric fusion proteins, with traverse. Applicants reserve the right to pursue non-elected subject matter in a continuation or divisional application. No claim has been added or amended by way of this response.

Respectfully submitted,



Scott N. Bernstein

Attorney for Applicants

Registration No.: 38,827

Phone: (805) 447-4128

Date: June 25, 2002

Please send all future correspondence to:

US Patent Operations/ SNB
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☒ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.
As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.